Patents by Inventor Blake Tomkinson

Blake Tomkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN
    Publication number: 20230405008
    Abstract: The present disclosure provides methods for treating hematological malignancies using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 21, 2023
    Inventors: Francis BURROWS, Blake TOMKINSON
  • COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
    Publication number: 20220088194
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: May 19, 2021
    Publication date: March 24, 2022
    Inventors: Blake TOMKINSON, Blake T. AFTAB, Byron C. HANN, Thomas G. MARTIN, III
  • COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE
    Publication number: 20200046832
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: June 5, 2019
    Publication date: February 13, 2020
    Inventors: Byron C. HANN, Blake TOMKINSON, Thomas G. MARTIN, III, Blake T. AFTAB
  • COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
    Publication number: 20190321471
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: April 4, 2019
    Publication date: October 24, 2019
    Inventors: Blake TOMKINSON, Blake T. AFTAB, Byron C. HANN, Thomas G. MARTIN, III
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20190284294
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 19, 2019
    Inventors: Antoine DESLANDES, Krzysztof J. GRZEGORZEWSKI, Marie-Laure OZOUX, Blake TOMKINSON
  • Compositions comprising anti-CD38 antibodies and lenalidomide
    Patent number: 10342869
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: July 9, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANOFI
    Inventors: Byron C. Hann, Blake Tomkinson, Thomas G. Martin, III, Blake T. Aftab
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20180022814
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 25, 2018
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
    Publication number: 20170106085
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 20, 2017
    Inventors: Blake TOMKINSON, Blake T. AFTAB, Byron C. HANN, Thomas G. MARTIN, III
  • COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
    Publication number: 20160022813
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Blake TOMKINSON, Blake T. AFTAB, Byron C. HANN, Thomas G. MARTIN, III
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20150118251
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 30, 2015
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • Compositions Comprising Anti-CD38 Antibodies and Lenalidomide
    Publication number: 20140161819
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 12, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANOFI
    Inventors: Byron C. Hann, Blake Tomkinson, Thomas G. Martin, III, Blake T. Aftab